Arrevus is a biotechnology company addressing the threat of antibiotic resistance with an effort to improve treatment outcomes for serious infectious diseases. With a focus on drug development for those diseases for which antibiotic resistance has important clinical implications - and for which few therapies exist - the firm's efforts organize around applying evolutionary templates to develop first-in-class proprietary anti-infectives known as Designer Proline-rich Antimicrobial Peptide Chaperone Protein Inhibitors (DPCs). The firm's is developing chaperone protein inhibitors, derived from host defense peptides (HDPs) found in insects and engineered to make these agents both safe and effective in mammalian tissues. The firm's lead compound has been optimized for Gram-negative pathogens and subsequent analogs will focus on areas of infectious disease with serious unmet need. In November 2021, it was announced that firm had been acquired by NovaQuest-backed Aceragen.
